No­var­tis rais­es the temp on Eylea ri­val­ry with head-to-head tri­al win for Beovu in di­a­bet­ic mac­u­lar ede­ma

Re­gen­eron’s an­ti-VEGF Eylea has long dom­i­nat­ed its mar­ket, but com­peti­tors are look­ing to de­throne the king — par­tic­u­lar­ly No­var­tis’ late­com­er Beovu. Ham­pered by pri­or safe­ty con­cerns …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER